연구성과로 돌아가기

2023 연구성과 (196 / 285)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
WoS SCOPUS Document Type Document Title Abstract Authors Affiliation ResearcherID (WoS) AuthorsID (SCOPUS) Author Email(s) Journal Name JCR Abbreviation ISSN eISSN Volume Issue WoS Edition WoS Category JCR Year IF JCR (%) FWCI FWCI Update Date WoS Citation SCOPUS Citation Keywords (WoS) KeywordsPlus (WoS) Keywords (SCOPUS) KeywordsPlus (SCOPUS) Language Publication Stage Publication Year Publication Date DOI JCR Link DOI Link WOS Link SCOPUS Link
Article Performance of Inclined-Plate Settler and Activated Carbon Sponge-Cube Media Filter for the Treatment of Urban Stormwater Runoff from an Industrial Complexs Urban stormwater runoff contributes to the deterioration of water quality of urban waterbodies. Development of a cost-effective treatment system that renders the treated effluent suitable for the recharge of receiving waterbodies meeting stringent regulations is required. This study evaluated the performances of the inclined-plate settler (IPS) and activated carbon sponge-cube media filter (ASMF) in treating urban stormwater runoff from an industrial complex area. The stormwater runoff during the first hour of rainfall had significantly high concentrations of suspended solids (SS), chemical oxygen demand (COD), and total nitrogen. The IPS and ASMF bed with hydraulic retention times of 15 & PLUSMN; 5 and < 3 min showed the removal efficiency of 5.4 - 33.2% and 32.8 - 95.1% for SS, turbidity, COD, and TP including < 5 - 20% for TN. The combined IPS/ASMF or biofilm (BF)-ASMF system at filtration velocity of 10 m/h showed removal efficiencies of 46.7 - 99.2% for insoluble fractions such as turbidity, COD, TP and heavy metals including < 40% for TN. The ASMF or BF-ASMF bed coupled with IPS is a cost-effective option for the treatment of urban stormwater runoff, achieving an effluent quality suitable for industrial or multipurpose reuse and for the recharge of waterbodies. Hyun, Kilsoo; Kang, Yongtae Kyungpook Natl Univ, Dept Environm & Safety Engn, Sangju 37224, South Korea; Dong A Univ, Dept Civil Engn, Pusan 49315, South Korea 34872168300; 7402784421 kshyun@knu.ac.kr; KSCE JOURNAL OF CIVIL ENGINEERING KSCE J CIV ENG 1226-7988 1976-3808 27 9 SCIE ENGINEERING, CIVIL 2023 1.9 49.7 0.12 2025-06-25 2 2 Urban stormwater runoff; Inclined-plate settler; Activated carbon sponge-cube media; High-rate filter; Biofiltration; Reclamation and reuse PARTICLE-SIZE DISTRIBUTION; WATER; PRETREATMENT; FILTRATION; SEAWATER; QUALITY; FLOW Activated carbon sponge-cube media; Biofiltration; High-rate filter; Inclined-plate settler; Reclamation and reuse; Urban stormwater runoff Activated carbon treatment; Chemical oxygen demand; Cost effectiveness; Deterioration; Efficiency; Effluent treatment; Effluents; Geometry; Heavy metals; Runoff; Storm sewers; Storms; Water quality; Activated carbon sponge-cube medium; Biofiltrations; High rate; High-rate filter; Inclined plate; Inclined-plate settler; Medium filter; Reclamation and reuse; Urban stormwater runoff; Waterbodies; Activated carbon English 2023 2023-09 10.1007/s12205-023-2307-y 바로가기 바로가기 바로가기 바로가기
Article Effectiveness and safety of adalimumab in patients with intestinal Behçet's disease: a real-world prospective observational study in South Korea BackgroundIntestinal Behcet's disease (BD) is characterized by typical gastrointestinal ulcers in patients with BD followed by complications such as bleeding, perforation and fistula. Biologic agents are currently under active investigation to delay the disease course. Various data regarding infliximab are available, but there is relatively lack of data regarding adalimumab.MethodsThis was a multicenter, real-world prospective observational study to evaluate the effectiveness and safety of adalimumab in intestinal BD. The primary endpoint was disease activity at each follow up, including disease activity index for intestinal Behcet's disease (DAIBD), serum C-reactive protein (CRP) level, and endoscopic findings. The secondary endpoint was the incidence of adverse drug reactions (ADRs).ResultsA total of 58 patients were enrolled and 8 of them were excluded. Adverse events were reported in 72.0% of patients with 122 events. ADRs were reported in 24.0% with 28 events. For adverse events, arthralgia was most commonly reported (13.1%: 16/122) and only one experienced critical adverse event (0.82%, 1/122: death due to stroke). On multivariable regression analysis, a longer disease duration was significantly associated with decreased ADRs [Odds ratio 0.976 (0.953-0.999, 95% CI); p = 0.042]. Clinical response rates as assessed by DAIBD were 90.9% at Week 12 and 89.7% at Week 56, respectively. The mean serum CRP level at baseline was significantly decreased after 12 weeks (3.91 +/- 4.93 to 1.26 +/- 2.03 mg/dL; p = 0.0002).ConclusionAdalimumab was found to be safe and effective in Korean patients with intestinal BD. A longer disease duration was significantly associated with decreased ADRs. Yu, Jongwook; Shin, Sung Jae; Park, Yune-Jung; Kim, Hyung Wook; Lee, Bo-In; Ye, Byong Duk; Kim, Geun-Tae; Kim, Sung Kook; Kim, Joo Sung; Kim, Young-Ho; Jeong, Seonjeong; Cheon, Jae Hee Yonsei Univ, Coll Med, Inst Gastroenterol, Dept Internal Med, 50-1 Yonsei Ro, Seoul 03722, South Korea; Ajou Univ, Sch Med, Dept Gastroenterol, Suwon, South Korea; Catholic Univ Korea, St Vincents Hosp, Dept Internal Med, Div Rheumatol, Suwon, South Korea; Pusan Natl Univ, Yangsan Hosp, Dept Internal Med, Yangsan, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Div Gastroenterol,Dept Internal Med, Seoul, South Korea; Univ Ulsan, Asan Med Ctr, Dept Gastroenterol, Coll Med, Seoul, South Korea; Univ Ulsan, Inflammatory Bowel Dis Ctr, Asan Med Ctr, Coll Med, Seoul, South Korea; Kosin Univ, Coll Med, Dept Internal Med, Pusan, South Korea; Kyungpook Natl Univ Hosp, Dept Internal Med, Daegu, South Korea; Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul, South Korea; Seoul Natl Univ, Liver Res Inst, Coll Med, Seoul, South Korea; Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med, Seoul, South Korea; AbbVie Korea Ltd, Seoul, South Korea Cheon, Jung-Eun/J-5684-2012; Ye, Byong/AAF-4955-2020; Kim, Seong Cheol/ABD-1493-2022; Kim, Jung/D-3112-2015; Cheon, Jae Hee/B-4523-2015; Kwak, Sang Gyu/AAG-4341-2021; Yu, Jongwook/HMV-5712-2023 57015768000; 57221641429; 55236811400; 56231863100; 8623333800; 57226091126; 56013410100; 34770060400; 7601375616; 57210738018; 58771937100; 35200350500 geniushee@yuhs.ac; BMC GASTROENTEROLOGY BMC GASTROENTEROL 1471-230X 23 1 SCIE GASTROENTEROLOGY & HEPATOLOGY 2023 2.5 50.0 0.39 2025-06-25 0 2 Behcet's syndrome; Adalimumab; Inflammatory bowel Diseases; Tumor necrosis factor-alpha ANTI-TNF-ALPHA; BEHCETS-DISEASE; EFFICACY; MULTICENTER; INFLIXIMAB; MAINTENANCE; MANAGEMENT; DIAGNOSIS; REMISSION; OUTCOMES Adalimumab; Behçet’s syndrome; Inflammatory bowel Diseases; Tumor necrosis factor-alpha Adalimumab; Behcet Syndrome; Humans; Infliximab; Intestinal Diseases; Intestines; adalimumab; C reactive protein; tumor necrosis factor; adalimumab; infliximab; arthralgia; Article; Behcet disease; cerebrovascular accident; controlled study; disease activity; disease association; disease duration; drug efficacy; drug safety; endoscopy; follow up; human; incidence; inflammatory bowel disease; multivariate logistic regression analysis; observational study; prospective study; protein blood level; South Korea; clinical trial; complication; enteropathy; intestine; multicenter study English 2023 2023-12-19 10.1186/s12876-023-03090-x 바로가기 바로가기 바로가기 바로가기
Article Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority study BackgroundProton-pump inhibitors (PPIs) are the most effective drugs for treating acid-related disorders. However, once-daily dosing with conventional PPIs fail to fully control acid secretion over 24 h. This study aimed to compare the efficacy and safety of HIP1601 (dual delayed-release esomeprazole) and HGP1705 (delayed-release esomeprazole) in patients with erosive esophagitis (EE).MethodsWe enrolled 213 patients with EE randomized in a 1:1 ratio to receive 40 mg HIP1601 (n = 107) or HGP1705 (n = 106) once daily for 4 or 8 weeks. The primary endpoint was the EE healing rate, confirmed by endoscopy up to week 8. GERD-related symptoms and treatment-emergent adverse events were compared between both groups.ResultsBy week 8, the estimated healing rates of EE were 97.8% and 96.8% in the HIP1601 and HGP1705 groups, respectively, with a 95% confidence interval of -4.7 to 7.2. After 4 or 8 weeks of treatment, the EE healing rate at week 4, complete resolution rate of symptoms, time to sustained resolution of symptoms, and number of rescue medications used were similar in both groups. The proportion of heartburn- and acid regurgitation-free nights by week 4 were higher in the HIP1601 group compared to the HGP1705 group, but the difference did not reach clinical significance (87.7% vs. 85.8%, P = 0.514, 87.5% vs. 85.8%, P = 0.774). The number of adverse events did not differ significantly between the two groups.ConclusionsThe efficacy and safety of HIP1601 40 mg were comparable to those of HGP1705 40 mg for the treatment of EE and symptomatic improvement of GERD.Trial registrationNCT04080726 (https://classic.clinicaltrials.gov/ct2/show/NCT04080726), registration date: 25/10/2018. Lim, Hyun; Park, Jong Kyu; Chung, Hyunsoo; Lee, Si Hyung; Park, Jae Myung; Park, Jung Ho; Kim, Gwang Ha; Shin, Sung Kwan; Hong, Su Jin; Lee, Kwang Jae; Park, Moo In; Jung, Hye-Kyung; Kim, Hyun-Soo; Sung, Jae Kyu; Jeon, Seong Woo; Choi, Suck Chei; Moon, Jeong Seop; Kim, Nayoung; Park, Jong-Jae; Hong, Sung Hee; Kim, Na Young; Jung, Hwoon-Yong Hallym Univ, Coll Med, Hallym Univ Sacred Heart Hosp, Dept Internal Med, Anyang, South Korea; Univ Ulsan, Coll Med, Gangneung Asan Hosp, Div Gastroenterol,Dept Internal Med, Kangnung, South Korea; Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Seoul Natl Univ, Coll Med, Liver Res Inst, Seoul, South Korea; Yeungnam Univ, Coll Med, Dept Internal Med, Daegu, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Internal Med, Seoul, South Korea; Sungkyunkwan Univ, Coll Med, Kangbuk Samsung Hosp, Dept Internal Med, Seoul, South Korea; Pusan Natl Univ, Dept Internal Med, Biomed Res Inst, Pusan Natl Univ Hosp,Sch Med, Pusan, South Korea; Yonsei Univ, Coll Med, Dept Internal Med, Div Gastroenterol,Inst Gastroenterol, Seoul, South Korea; SoonChunHyang Univ, Digest Dis Ctr & Res Inst, Dept Internal Med, Coll Med, Bucheon, South Korea; Ajou Univ, Sch Med, Dept Gastroenterol, Suwon, South Korea; Kosin Univ, Coll Med, Dept Internal Med, Busan, South Korea; Ewha Womans Univ, Sch Med, Dept Internal Med, Seoul, South Korea; Chonnam Natl Univ Hosp, Dept Internal Med, Gwangju, South Korea; Chungnam Natl Univ, Coll Med, Dept Internal Med, Daejeon, South Korea; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; Wonkwang Univ Hosp, Digest Dis Res Inst, Dept Gastroenterol, Iksan, South Korea; Inje Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Seongnam, South Korea; Korea Univ, Coll Med, Dept Internal Med, Div Gastroenterol,Guro Hosp, Seoul, South Korea; Hanmi Pharmaceut Co Ltd, Seoul, South Korea; Univ Ulsan, Coll Med, Asan Med Ctr, Dept Gastroenterol, Seoul, South Korea Kim, Gwang Ha/ABF-3932-2021; Kim, Hong/AAR-4892-2020; Lee, Si/ABH-1408-2020; Kim, Na/A-8115-2008; Park, Jae Myung/AGK-6655-2022; Kim, Nayoung/J-5387-2012; 박, 진화/GYV-5685-2022; Jeon, Seongwoo/AAU-4618-2020 55616390700; 36537734300; 56403766700; 35771122400; 8548758100; 57206477427; 35214772400; 57226038279; 35285527200; 35345240300; 8666034000; 7403029723; 57210863499; 8439931900; 9733636500; 7408119608; 36942318200; 57201181440; 34668368400; 57463312700; 59295316300; 7403029804 hwoonymd@gmail.com; BMC GASTROENTEROLOGY BMC GASTROENTEROL 1471-230X 23 1 SCIE GASTROENTEROLOGY & HEPATOLOGY 2023 2.5 50.0 0.2 2025-06-25 2 1 Proton pump inhibitor; HIP1601; Esomeprazole; Gastroesophageal reflux disease GASTROESOPHAGEAL-REFLUX DISEASE; QUALITY-OF-LIFE; OMEPRAZOLE; PHARMACODYNAMICS; PHARMACOKINETICS; QUESTIONNAIRE; LANSOPRAZOLE; PANTOPRAZOLE; FORMULATION; VALIDATION Esomeprazole; Gastroesophageal reflux disease; HIP1601; Proton pump inhibitor Double-Blind Method; Esomeprazole; Esophagitis; Esophagitis, Peptic; Gastroesophageal Reflux; Humans; Peptic Ulcer; Proton Pump Inhibitors; Treatment Outcome; esomeprazole; esomeprazole; proton pump inhibitor; adult; aged; Article; controlled study; delayed release formulation; double blind procedure; drug dosage form comparison; drug efficacy; drug safety; drug tolerability; dysphagia; epigastric pain; esophagoscopy; female; gastroesophageal reflux; healing rate; heartburn; human; major clinical study; male; middle aged; multicenter study; non-inferiority trial; patient compliance; randomized controlled trial; reflux esophagitis; treatment duration; treatment outcome; unspecified side effect; young adult; clinical trial; esophagitis; gastroesophageal reflux; peptic ulcer English 2023 2023-12-18 10.1186/s12876-023-03087-6 바로가기 바로가기 바로가기 바로가기
Review Korean guidelines for the management of gout Gout is the most common form of arthritis, with the prevalence increasing worldwide. The present treatment guidelines provide recommendations for the appropriate treatment of acute gout, management during the inter-critical period, and prevention of chronic complications. The guidelines were developed based on evidence-based medicine and draft recommendations finalized after expert consensus. These guidelines are designed to provide clinicians with clinical evidence to enable efficient treatment of gout. Lee, Jennifer Jooha; Lee, Ji Soo; Chung, Min Kyung; Ahn, Joong Kyong; Choi, Hyo-Jin; Hong, Seung-Jae; Yoon, Chong-Hyeon; Kim, Su-Hyun; Jeong, Kyung-Hwan; Kim, Jong -Woo; Kim, Bo-Yeon; Shin, Jin-Ho; Kim, Woo Gyu; Kim, Soo -Young; Kim, Hyun-Jung; Song, Jeong-Soo; Jun, Jae-Bum; Park, Hyun-Ah; Chae, Shung Chull; Choi, Bum Soon; Kim, Tae Nyun; Kim, Hyun Ah Catholic Univ Korea, Coll Med, Dept Internal Med, Div Rheumatol, Seoul, South Korea; Ewha Womans Univ, Sch Med, Dept Internal Med, Div Rheumatol, Seoul, South Korea; Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Internal Med,Div Rheumatol, Seoul, South Korea; Gachon Univ, Coll Med, Gil Med Ctr, Dept Internal Med,Div Rheumatol, Incheon, South Korea; Kyung Hee Univ, Kyung Hee Univ Hosp, Sch Med, Dept Internal Med,Div Rheumatol, Seoul, South Korea; Chung Ang Univ, Sch Med, Dept Internal Med, Div Nephrol, Seoul, South Korea; Kyung Hee Univ, Med Ctr, Dept Internal Med, Div Nephrol, Seoul, South Korea; Inje Univ, Sanggye Paik Hosp, Coll Med, Dept Family Med, Seoul, South Korea; Soonchunhyang Univ, Bucheon Hosp, Coll Med, Dept Internal Med,Div Endocrinol & Metab, Bucheon, South Korea; Hanyang Univ, Coll Med, Dept Internal Med, Div Cardiol, Seoul, South Korea; Lights & Salt Internal Med, Goyang, South Korea; Hallym Univ, Kangdong Sacred Heart Hosp, Coll Med, Dept Family Med, Seoul, South Korea; Korea Univ, Inst Evidence Based Med, Coll Med, Dept Prevent Med,Cochrane Korea, Seoul, South Korea; Chung Ang Univ, Sch Med, Dept Internal Med, Div Rheumatol, Seoul, South Korea; Hanyang Univ Hosp Rheumat Dis, Dept Rheumatol, Seoul, South Korea; Inje Univ, Seoul Paik Hosp, Coll Med, Dept Family Med, Seoul, South Korea; Kyungpook Natl Univ Hosp, Dept Internal Med, Daegu, South Korea; Catholic Univ Korea, Coll Med, Dept Internal Med, Div Nephrol, Seoul, South Korea; Inje Univ, Haeundae Paik Hosp, Coll Med, Dept Internal Med,Div Endocrinol & Metab, Pusan, South Korea; Hallym Univ, Sacred Heart Hosp, Dept Internal Med, Div Rheumatol, Anyang, South Korea; Hallym Univ, Sacred Heart Hosp, Div Rheumatol, 22 Gwanpyeong Ro 170beon Gil, Anyang 14068, South Korea ; Kim, Su Hyun/JPY-2079-2023; Kim, Soo Young/GLR-4223-2022; Hyun-Jung, Kim/E-8074-2011; Kim, Tae/AAV-5521-2020 kimha@hallym.ac.kr; JOURNAL OF RHEUMATIC DISEASES J RHEUMAT DIS 2093-940X 2233-4718 30 3 ESCI RHEUMATOLOGY 2023 2.2 50.0 7 Gout; Guidelines; Treatment URATE-LOWERING THERAPY; SERUM URIC-ACID; DOUBLE-BLIND; FLARE PREVENTION; INITIATION; ALLOPURINOL; FEBUXOSTAT; COLCHICINE; RISK; PROPHYLAXIS English 2023 2023-07 10.4078/jrd.2023.0029 바로가기 바로가기 바로가기
Article Nearly flat bands and ferromagnetism in the terminated Mn2C MXene Using Density Functional Theory and Periodic Boundary Conditions it is shown that the hydroxylated/oxygenated/halogenated Mn2C monolayer is a 2D ferromagnetic material with a local Mn ions magnetic moment of 2.7 mu B per unit cell. Upon oxygenation the ferromagnetic coupling between Mn ions can be transformed into a superposition of magnetic states. In particular, the intrinsic magnetic moments in the hydroxylated/halogenated Mn2C monolayer can attain up to 6 mu B per unit cell. It is found that oxygen termination induces flat bands in the band structure, which evidence for the strong electron correlations and could lead to the implementation of exotic quantum phases in 2D crystals and high-temperature superconductivity. Along with the potential of the hydroxylated Mn2C monolayer characterized by the half-metallicity for application in spintronic devices as a perfect spin injector/detector, this material like other conventional MXenes is promising for the use in energy storage, electromagnetic interference shielding, and sensing. Kozak, Victoria V.; Fedorova, Natalja A.; Olshevskaya, Julia S.; Kovaleva, Alena, V; Shubin, Alexander A.; Tarasov, Anton S.; Varnakov, Sergey N.; Ovchinnikov, Sergei G.; Tomilin, Felix N.; Avramov, Pavel, V Fed Res Ctr KSC SB RAS, Kirensky Inst Phys, Krasnoyarsk 660036, Russia; Siberian Fed Univ, Krasnoyarsk 660041, Russia; Kyungpook Natl Univ, Coll Nat Sci, Dept Chem, 80 Daehak Ro, Daegu 41566, South Korea ; Tarasov, Anton/P-3734-2015; Tomilin, Felix/F-3763-2014; Varnakov, Sergey/A-5392-2014; Shubin, Aleksandr/J-7025-2012; Olshevskaya, Julia/AAT-9801-2021; Kozak, Victoria/HMP-4669-2023 57904219000; 57903802100; 58188494300; 57904008500; 57201082401; 55417660400; 6602656052; 14122071800; 6602246772; 7004322420 felixnt@gmail.com;paul.veniaminovich@knu.ac.kr; COMPUTATIONAL CONDENSED MATTER COMPUT CONDENS MATTE 2352-2143 35 ESCI PHYSICS, CONDENSED MATTER 2023 2.6 50.0 0.41 2025-06-25 2 3 MXene; Nanomaterials; B3LYP; Ferromagnet; Spintronics; 2D magnetism; Half metal; Hydroxylated; oxygenated; halogenated MXene METAL; TRANSITION; DENSITY; SPINTRONICS; TEMPERATURE; MONOLAYER; STABILITY; STATES 2D magnetism; B3LYP; Ferromagnet; Half metal; Hydroxylated/oxygenated/halogenated MXene; MXene; Nanomaterials; Spintronics English 2023 2023-06 10.1016/j.cocom.2023.e00806 바로가기 바로가기 바로가기 바로가기
Article Outbreak of severe diarrhea due to zoonotic Cryptosporidium parvum and C. xiaoi in goat kids in Chungcheongbuk-do, Korea Severe diarrhea was reported in goat kids in Chungcheongbuk-do, Korea, from 2021 to 2023, and Cryptosporidium infection was suspected. To confirm the cause of this outbreak, fecal samples were collected from goat farms where diarrhea had been reported and analyzed for Cryptosporidium infection using a molecular assay. A total of 65 fecal samples, including 37 from goats with diarrhea and 28 from goats without diarrhea, were collected from six goat farms. Forty-eight of the goats were kids (1 year). Cryptosporidium was identified in 53.8% (35/65) of total samples. Overall, 86.5% (32/37) of the diarrheic fecal samples tested positive; however, Cryptosporidium was not detected in any fecal sample from non-diarrheic adult goats. Therefore, cryptosporidiosis was significantly associated with diarrhea in goat kids, and adult goats were not responsible for transmission of Cryptosporidium to them. Phylogenetic analysis and molecular characterization revealed two Cryptosporidium species, namely, C. parvum (n = 28) and C. xiaoi (n = 7). In the C. parvum-positive samples, gp60 gene analysis revealed three zoonotic subtypes-IIaA18G3R1, IIdA15G1, and IIdA16G1. To the best of our knowledge, this study is the first to identify C. parvum IIaA18G3R1 and IIdA16G1 in goats, as well as the first to identify C. xiaoi in goats in Korea. These results suggest that goat kids play an important role as reservoir hosts for different Cryptosporidium species and that continuous monitoring with biosecurity measures is necessary to control cryptosporidiosis outbreaks. Kim, Ah-Young; Alkathiri, Badriah; Lee, Subin; Min, Kyung-Duk; Kim, Soochong; Lee, Sang-Myeong; Lee, Wan-Kyu; Kwak, Dongmi; Lee, Seung-Hun Agr Policy Bur, Anim Quarantine Div, Cheongju, Chungcheongbugd, South Korea; Chungbuk Natl Univ, Grad Vet Biosecur & Protect, Cheongju, South Korea; Chungbuk Natl Univ, Coll Vet Med, Cheongju, South Korea; Kyungpook Natl Univ, Coll Vet Med, Daegu, South Korea 58354643300; 57190979864; 57776738900; 57218662067; 7601600702; 36062712900; 56164987700; 7007148758; 57203394416 aykim0612@korea.kr;badara25.ba@gmail.com;tnqls7488@naver.com;kdmin@chungbuk.ac.kr;skim0026@chungbuk.ac.kr;smlee@chungbuk.ac.kr;wklee@chungbuk.ac.kr;dmkwak@knu.ac.kr;dvmshlee@chungbuk.ac.kr; PARASITOLOGY RESEARCH PARASITOL RES 0932-0113 1432-1955 122 9 SCIE PARASITOLOGY 2023 1.8 50.0 0.85 2025-06-25 4 4 Cryptosporidiosis; Cryptosporidium parvum; Cryptosporidium xiaoi; Goat; Diarrhea; Outbreak MOLECULAR CHARACTERIZATION; SUBTYPE ANALYSIS; SPP.; LAMBS; PREVALENCE; INFECTION; GENOTYPES; FARM; PROVINCE; GIARDIA Cryptosporidiosis; Cryptosporidium parvum; Cryptosporidium xiaoi; Diarrhea; Goat; Outbreak Animals; Cryptosporidiosis; Cryptosporidium; Cryptosporidium parvum; Diarrhea; Disease Outbreaks; Feces; Genotype; Goat Diseases; Goats; Phylogeny; Republic of Korea; Sheep; Sheep Diseases; agricultural land; animal experiment; animal tissue; Article; biosecurity; controlled study; cryptosporidiosis; Cryptosporidium parvum; diarrhea; feces; feces analysis; female; kid (goat); Korea; male; nonhuman; phylogeny; prevalence; animal; cryptosporidiosis; Cryptosporidium; diarrhea; epidemic; genetics; genotype; goat; goat disease; sheep; sheep disease; South Korea; veterinary medicine English 2023 2023-09 10.1007/s00436-023-07904-5 바로가기 바로가기 바로가기 바로가기
Article Tumor-like Presentation of Cerebral Vasculitis in a Patient With Systemic Lupus Erythematosus: A Biopsy-confirmed Case Central nervous system (CNS) manifestations of systemic lupus erythematosus (SLE) are diverse and often difficult to distinguish from SLE-unrelated events. CNS vasculitis is a rare manifestation, which is seen in less than 10% of post-mortem studies, and lesions with multifocal cerebral cortical microinfarcts associated with small-vessel vasculitis are the predominant feature. How-ever, CNS vasculitis presenting as a tumor-like mass lesion in SLE has rarely been reported. Herein, we report a case of cerebral vasculitis mimicking a brain tumor in a 39-year-old female with SLE. A biopsy of the brain mass revealed fibrinoid necrosis and leukocytoclastic vasculitis. The neurological deficits and systemic symptoms improved after treatment with corticosteroids and immunosuppressive agents. To the best of our knowledge, there are no reports of biopsy-proven cerebral vasculitis presenting as a brain mass in patients with SLE in Korea. Kim, Na Ri; Kang, Jong Wan; Nam, Eon Jeong Kyungpook Natl Univ, Sch Med, Dept Internal Med, Div Rheumatol, 807 Hoguk Ro, Daegu 41404, South Korea; Daegu Fatima Hosp, Dept Internal Med, Div Rheumatol, Daegu, South Korea 58113116000; 57212803692; 7005824293 ejnam@knu.ac.kr; JOURNAL OF RHEUMATIC DISEASES J RHEUMAT DIS 2093-940X 2233-4718 30 1 ESCI RHEUMATOLOGY 2023 2.2 50.0 0.6 2025-06-25 2 3 Central nervous system vasculitis; Systemic lupus erythematosus; Tumor; Biopsy Biopsy; Central nervous system vasculitis; Systemic lupus erythematosus; Tumor corticosteroid; creatinine; cyclophosphamide; eculizumab; glycoprotein; immunosuppressive agent; methylprednisolone; mycophenolate mofetil; neutrophil cytoplasmic antibody; pazopanib; prednisone; rituximab; tacrolimus; adult; Article; brain biopsy; brain vasculitis; case report; cell infiltration; central nervous system; clinical article; computer assisted tomography; echocardiography; erythrocyte sedimentation rate; female; fibrinoid necrosis; hemodialysis; hospital readmission; human; immunosuppressive treatment; intracranial pressure; kidney biopsy; kidney function; leukocyte count; lumbar puncture; nephrology; nephrotoxicity; nuclear magnetic resonance imaging; ophthalmoscopy; physical examination; protein creatinine ratio; small vessel vasculitis; systemic lupus erythematosus; thrombotic thrombocytopenic purpura; urea nitrogen blood level; urinalysis English 2023 2023-01 10.4078/jrd.22.0022 바로가기 바로가기 바로가기 바로가기
Article Multi-MicroRNA Analysis Can Improve the Diagnostic Performance of Mammography in Determining Breast Cancer Risk The objective of this study was to determine whether multi-microRNA analysis using a combination of four microRNA biomarkers (miR-1246, 202, 21, and 219B) could improve the diagnostic performance of mammography in determining breast cancer risk by age group (under 50 vs. over 50) and distinguish breast cancer from benign breast diseases and other cancers (thyroid, colon, stomach, lung, liver, and cervix cancers). To verify breast cancer classification performance of the four miRNA biomarkers and whether the model providing breast cancer risk score could distinguish between benign breast disease and other cancers, the model was verified using nonlinear support vector machine (SVM) and generalized linear model (GLM) and age and four miRNA qRT-PCR analysis values (dCt) were input to these models. Breast cancer risk scores for each Breast Imaging-Reporting and Data System (BI-RADS) category in multi-microRNA analysis were analyzed to examine the correlation between breast cancer risk scores and mammography categories. We generated two models using two classification algorithms, SVM and GLM, with a combination of four miRNA biomarkers showing high performance and sensitivities of 84.5% and 82.1%, a specificity of 85%, and areas under the curve (AUCs) of 0.967 and 0.965, respectively, which showed consistent performance across all stages of breast cancer and patient ages. The results of this study showed that this multi-microRNA analysis using the four miRNA biomarkers was effective in classifying breast cancer in patients under the age of 50, which is challenging to accurately diagnose. In addition, breast cancer and benign breast diseases can be classified, showing the possibility of helping with diagnosis by mammography. Verification of the performance of the four miRNA biomarkers confirmed that multi-microRNA analysis could be used as a new breast cancer screening aid to improve the accuracy of mammography. However, many factors must be considered for clinical use. Further validation with an appropriate screening population in large clinical trials is required. This trial is registered with (KNUCH 2022-04-036). Song, Ji-Eun; Jang, Ji Young; Kang, Kyung Nam; Jung, Ji Soo; Kim, Chul Woo; Kim, Ah Sol Kyungpook Natl Univ, Dept Family Med, Chilgok Hosp, 807 Hoguk Ro, Daegu 41404, South Korea; BIOINFRA Life Sci Inc, Seoul 03127, South Korea Kim, Sang/J-5399-2012; Song, Jieun/LLM-7026-2024 57217295366; 7402965135; 35277947600; 58797056500; 20234820300; 57203290656 love2uje@naver.com;jiyoung.jang@bioinfra.co.kr;kyungnam.kang@bioinfra.co.kr;jisoo.jung@bioinfra.co.kr;chulwoo.kim@bioinfra.co.kr;deepai@knu.ac.kr; BREAST JOURNAL BREAST J 1075-122X 1524-4741 2023 SCIE OBSTETRICS & GYNECOLOGY;ONCOLOGY 2023 1.9 50.4 0.22 2025-06-25 0 1 SCREENING MAMMOGRAPHY; DISEASE; UPDATE; WOMEN Biomarkers; Breast; Breast Neoplasms; Female; Fibrocystic Breast Disease; Humans; Mammography; MicroRNAs; biological marker; microRNA; microRNA 1246; microRNA 202; microRNA 21; microRNA 219b; unclassified drug; biological marker; microRNA; adult; aged; Article; benign breast disease; breast cancer; breast imaging reporting and data system; cancer classification; cancer risk; cancer screening; classification algorithm; cohort analysis; colon cancer; colorectal cancer; controlled study; diagnostic test accuracy study; diagnostic value; differential diagnosis; female; groups by age; human; liver cancer; liver cell carcinoma; lung cancer; major clinical study; mammography; middle aged; real time reverse transcription polymerase chain reaction; retrospective study; RNA analysis; sensitivity and specificity; stomach cancer; support vector machine; thyroid cancer; uterine cervix cancer; breast; breast tumor; diagnostic imaging; fibrocystic breast disease; genetics; mammography; procedures English 2023 2023-12-27 10.1155/2023/9117047 바로가기 바로가기 바로가기 바로가기
Article Evaluation of Radiation Sensitivity Differences in Mouse Liver Tumor Organoids Using CRISPR/Cas9-Mediated Gene Mutation Background: To assess the radiosensitivity of liver tumors harboring different genetic mutations, mouse liver tumors were generated in vivo through the hydrodynamic injection of clustered regularly interspaced short palindromic repeat/caspase 9 (CRISPR/Cas9) constructs encoding single-guide RNAs (sgRNAs) targeting Tp53, Pten, Nf1, Nf2, Tsc2, Cdkn2a, or Rb1. Methods: The plasmid vectors were delivered to the liver of adult C57BL/6 mice via hydrodynamic tail vein injection. The vec-tors were injected into 10 mice in each group. Organoids were generated from mouse liver tumors. The radiation response of the organoids was assessed using an ATP cell viability assay. Results: The mean survival period of mice injected with vectors targeting Nf2 (4.8 months) was lower than that of other mice. Hematoxylin and eosin staining, immunohistochemical (IHC) stain-ing, and target sequencing analyses revealed that mouse liver tumors harbored the expected mutations. Tumor organoids were established from mouse liver tumors. Histological evaluation revealed marked morphological similarities between the mouse liver tumors and the generated tumor organoids. Moreover, IHC staining indicated that the parental tumor protein expression pattern was maintained in the organoids. The results of the ATP cell viability assay revealed that the tumor organoids with mutated Nf2 were more resistant to high-dose radiation than those with other gene mutations. Conclusions: This study developed a radi-ation response assessment system for mouse tumors with mutant target genes using CRISPR/Cas9 and organoids. The Tp53 and Pten double mutation in combination with the Nf2 mutation increased the radiation resistance of tumors. The system used in this study can aid in elucidating the mechanism underlying differential intrinsic radiation sensitivity of individual tumors. Jeon, Wan; Jung, Se Yeon; Lee, Chae Young; Kim, Won-Tae; Kim, Hyun; Jang, Kyoung Won; Lim, Heuijin; Lee, Manwoo; Jeong, Dong Hyeok; Kim, Sung Dae; Kim, In Ah; Choi, Si Ho; Son, Tae Gen; Kim, Kyung Su Dongnam Inst Radiol & Med Sci, Dept Radiat Oncol, Busan, South Korea; Seoul Natl Univ, Coll Med, Dept Radiat Oncol, Seoul, South Korea; Dongnam Inst Radiol & Med Sci, Res Ctr, Busan, South Korea; Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Radiat Oncol, Seongnam, South Korea; Seoul Natl Univ Hosp, Dept Radiat Oncol, Seoul, South Korea; Kyungpook Natl Univ, Coll Vet Med, Dept Vet Med, Daegu, South Korea Kim, In/J-5426-2012; Kim, Kyoungmi/AEP-3965-2022 sihochoi@dirams.re.kr;tgson@dirams.re.kr;kskim.cirt@snu.ac.kr; TECHNOLOGY IN CANCER RESEARCH & TREATMENT TECHNOL CANCER RES T 1533-0346 1533-0338 22 SCIE ONCOLOGY 2023 2.7 50.5 3 CRISPR-Cas systems; liver; organoids; radiation tolerance; tumor English 2023 2023 10.1177/15330338231165125 바로가기 바로가기 바로가기
Article Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen Purpose To evaluate the safety and effectiveness of aflibercept in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) in Korean patients with metastatic colorectal cancer (mCRC) who progressed with oxaliplatin-containing regimen. Methods This was a prospective observational study conducted at 22 sites across Korea between February 2018 and September 2019. Patients aged > 19 years with a diagnosis of mCRC who were prescribed aflibercept plus FOLFIRI, after progression with an oxaliplatin-containing regimen were included. Disease assessment was performed every 6 weeks. Results A total of 185 patients were included (males, 58.9%; right-sided tumors, 23.8%; and ECOG performance factor >= 1, 68.6%). A total of 514 adverse events (AEs) occurred in 134 patients, of which 206 (49.2%; 95% CI 42.0%, 56.4%) events were considered as adverse drug reactions (ADRs), 172 unexpected AEs (49.7%; 95% CI 42.5%, 56.9%), and 53 serious AEs (22.2%; 95% CI16.2%, 28.2%). The most common serious ADR was pneumonia (n = 2, 1.6%). The most common all grade hematological AE and non-hematological AE were neutropenia (21.6%) and nausea (16.2%), respectively. Over a median follow-up of 5.6 months, a total of five grade 5 (1.0%) AEs were reported. Median OS was 9.4 months, and median progression-free survival (PFS) was 7.3 months. The overall response rate was 14.6%. Right-sided tumor location and prior bevacizumab treatment were independent factors of poor PFS in multivariate analysis. Conclusion Aflibercept in combination with FOLFIRI was effective and showed an acceptable safety profile in Korean patients with mCRC in daily clinical practice. Beom, Seung-Hoon; Kim, Jong Gwang; Baik, Seung Hyuk; Shin, Seong Hoon; Park, Inkeun; Park, Young Suk; Lee, Myung-Ah; Lee, Soohyeon; Jeon, So-Yeon; Han, Sae-Won; Kang, Myoung Hee; Oh, Jisu; Kim, Jin Soo; Kim, Jin Young; Ahn, Mi Sun; Zang, Dae Young; Bae, Byung-Noe; Jo, Hong Jae; Kim, Hee Kyung; Kim, Jung-Han; Yoon, Ji Ae; Kim, Dong Han Yonsei Univ, Dept Internal Med, Div Med Oncol, Coll Med, Seoul, South Korea; Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Oncol Hematol, 807 Hoguk Ro, Daegu 41404, South Korea; Yonsei Univ, Gangnam Severance Hosp, Dept Surg, Sect Colon & Rectal Surg,Coll Med, 211 Eonju Ro, Seoul, South Korea; Kosin Univ, Dept Internal Med, Gospel Hosp, Busan, South Korea; Gachon Univ, Dept Internal Med, Div Hematol Oncol, Gil Med Ctr, 774-21 Namdongdero, Incheon, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, 81 Irwon Ro, Seoul, South Korea; Catholic Univ Korea, Coll Med, Canc Res Inst, Div Med Oncol,Dept Internal Med,Seoul St Marys Ho, Seoul, South Korea; Korea Univ, Dept Internal Med, Div Oncol Hematol, Anam Hosp, 73 Goryeodae Ro Seongbuk Gu, Seoul 02841, South Korea; Jeonbuk Natl Univ, Dept Internal Med, Med Sch, Jeonju, South Korea; Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea; Seoul Natl Univ, Canc Res Inst, Seoul, South Korea; Gyeongsang Natl Univ, Coll Med, Dept Internal Med, Div Hematol Oncol,Changwon Hosp, Samjeongja Ro 11, Chang Won, South Korea; Yongin Severance Hosp, Dept Internal Med, Div Med Oncol, Yongin, Gyeonggi Do, South Korea; Chungnam Natl Univ, Coll Med, Dept Surg, Sejong Hosp, Sejong, South Korea; Keimyung Univ, Dept Internal Med, Div Hematol & Oncol, Dongsan Hosp, Daegu, South Korea; Ajou Univ, Dept Hematol Oncol, Sch Med, Suwon 16499, South Korea; Hallym Univ, Med Ctr, Dept Internal Med, Coll Med, Anyang Si, South Korea; Inje Univ, Coll Med, Dept Surg, Sanggye Paik Hosp, 1342 Dongil Ro, Seoul, South Korea; Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Surg, Sch Med, Busan, South Korea; Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Dept Internal Med, Div Oncol,Coll Med, Cheongju, South Korea; Hallym Univ, Kangnam Sacred Heart Hosp, Dept Internal Med, Coll Med, Seoul, South Korea; Sanofi Korea, Med Affairs Oncol, Seoul, South Korea; GSK Korea, Seoul, South Korea park, youngsuk/AAV-3491-2020; KIM, SUN/I-9389-2017; Kim, Donghee/C-4288-2013; Kim, Heui-Soo/ABF-3773-2021; Lee, Soohyeon/AAX-9843-2020 52563182100; 59501049300; 57293077900; 54978384000; 25947690900; 57225302903; 35227488700; 55176463100; 55194346500; 8363968600; 56557243800; 37038294200; 57049824000; 57196169650; 35885237100; 57216641597; 7007174517; 23110978100; 59052887200; 56588609200; 57554153900; 57554154000 jkk21c@knu.ac.kr; JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY J CANCER RES CLIN 0171-5216 1432-1335 149 3 SCIE ONCOLOGY 2023 2.7 50.5 0.3 2025-06-25 2 2 Acquired resistance; Anti-VEGF agents; Chemotherapy; Colorectal cancer ESMO CONSENSUS GUIDELINES; SIDED COLON-CANCER; 1ST-LINE TREATMENT; SUBGROUP ANALYSES; PLUS BEVACIZUMAB; OPEN-LABEL; FLUOROURACIL; LEUCOVORIN; IRINOTECAN; SURVIVAL Acquired resistance; Anti-VEGF agents; Chemotherapy; Colorectal cancer Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Male; Oxaliplatin; Rectal Neoplasms; Republic of Korea; aflibercept; analgesic agent; anticoagulant agent; antidiarrheal agent; antiemetic agent; antihistaminic agent; appetite stimulant; bevacizumab; blood substitute; calcium channel blocking agent; cetuximab; corticosteroid; fluorouracil; folinic acid; immunostimulating agent; irinotecan; oxaliplatin; vitamin; aflibercept; antineoplastic agent; bevacizumab; camptothecin; fluorouracil; folinic acid; oxaliplatin; abdominal distension; abdominal pain; acute heart infarction; acute kidney failure; adult; adverse drug reaction; aged; Article; asthenia; cancer combination chemotherapy; cancer growth; cancer patient; cholelithiasis; clinical evaluation; clinical practice; colitis; controlled study; decreased appetite; diarrhea; disease assessment; disease exacerbation; drug efficacy; drug safety; dyspepsia; dyspnea; embolism; enterocolitis; enterocutaneous fistula; febrile neutropenia; female; femur fracture; fever; follow up; genetic variation; hematologic disease; hematuria; hiccup; human; hydronephrosis; hypertension; ileus; insomnia; intestine obstruction; jaundice; Korean (people); large intestine perforation; liver failure; major clinical study; male; metastatic colorectal cancer; middle aged; multiple cycle treatment; multivariate analysis; muscle weakness; nausea; neutropenia; observational study; overall response rate; pancreatitis; perianal abscess; peripheral edema; peripheral neuropathy; peritonitis; pneumonia; prescription; progression free survival; prospective study; sepsis; stomatitis; transverse colon; treatment response; very elderly; colon tumor; colorectal tumor; pathology; rectum tumor; South Korea English 2023 2023-03 10.1007/s00432-022-03946-x 바로가기 바로가기 바로가기 바로가기
Article Hepatoprotective functions of jujuboside B Jujuboside B (JB) found in the seeds of Zizyphi Spinosi Semen possesses pharmacological functions, such as anti-inflammatory, antiplatelet aggregation, and antianxiety potentials. This study evaluated the effect of JB on liver failure in cecal ligation and puncture (CLP)-induced sepsis. First, we observed histopathological changes in the liver by optical microscopy and the activity of enzymes in serum such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST). We further measured the levels of interleukin (IL)-1 beta, tumor necrosis factor (TNF)-alpha, nitric oxide (NO), and antioxidative parameters in liver homogenate. The expression of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1), 11 beta-hydroxysteroid dehydrogenase type 2 (11 beta-HSD2), and glucocorticoid receptor (GR) in the liver was observed by Western blotting. CLP enhanced the migration of inflammatory cells, ALT and AST concentrations, and necrosis, which were reduced by JB. In addition, JB reduced 11 beta-HSD2 expression and levels of inflammatory mediators (TNF-alpha, IL-1 beta, and NO) in the liver, increased GR expression, enhanced endogenous antioxidative capacity. These results further suggest that JB may protect the liver against CLP-induced damage by regulating anti-inflammatory responses, downregulating 11 beta-HSD2 expression and antioxidation, and up-regulating GR expression. Kim, Chaeyeong; Jeong, Yun Hee; Kim, Nayeon; Ryu, Soo Ho; Bae, Jong-Sup Kyungpook Natl Univ, Res Inst Pharmaceut Sci, Coll Pharm, 80 Daehak Ro, Daegu 41566, South Korea; Korea Inst Oriental Med, Korean Med KM Applicat Ctr, Daegu 41062, South Korea Bae, Jong-Sup/AAU-9724-2020 57418696700; 55073020100; 57226179942; 57418127000; 16021543200 baejs@knu.ac.kr; JOURNAL OF NATURAL MEDICINES J NAT MED-TOKYO 1340-3443 1861-0293 77 1 SCIE CHEMISTRY, MEDICINAL;PHARMACOLOGY & PHARMACY 2023 2.5 50.7 0.99 2025-06-25 5 5 Jujuboside B; Liver injury; Inflammation; Glucocorticoid receptor; Antioxidative effect SEPSIS; LIVER; GLUCOCORTICOIDS; INFLAMMATION; MECHANISMS; EXPRESSION; HEALTH; INJURY; ALPHA Antioxidative effect; Glucocorticoid receptor; Inflammation; Jujuboside B; Liver injury 11-beta-Hydroxysteroid Dehydrogenase Type 2; Antioxidants; Glucocorticoids; Saponins; Tumor Necrosis Factor-alpha; 11beta hydroxysteroid dehydrogenase 1; 11beta hydroxysteroid dehydrogenase 2; alanine aminotransferase; aspartate aminotransferase; dexamethasone; glucocorticoid receptor; interleukin 1beta; jujuboside B; liver protective agent; nitric oxide; plant extract; tumor necrosis factor; unclassified drug; 11beta hydroxysteroid dehydrogenase 2; antioxidant; glucocorticoid; jujube extract; jujuboside B; saponin; tumor necrosis factor; alanine aminotransferase blood level; animal experiment; animal model; animal tissue; antiinflammatory activity; antioxidant activity; Article; aspartate aminotransferase blood level; cecal ligation and puncture-induced sepsis; cell migration; controlled study; down regulation; drug structure; enzyme activity; histopathology; inflammatory cell; jujube; liver failure; liver homogenate; liver injury; liver level; liver necrosis; liver protection; male; medicinal plant; microscopy; mouse; nonhuman; protein expression; upregulation; Western blotting English 2023 2023-01 10.1007/s11418-022-01648-9 바로가기 바로가기 바로가기 바로가기
Review The Complex Roles of DNA Repair Pathways, Inhibitors, Hyperthermia, and Contact Inhibition in Cell Cycle Halts The cell cycle has the capacity to safeguard the cell's DNA from damage. Thus, cell cycle arrest can allow tumor cells to investigate their own DNA repair processes. Cancer cells become extremely reliant on G1-phase cyclin-dependent kinases due to mutated oncogenes and deactivated tumor suppressors, producing replication stress and DNA damage during the S phase and destroying checkpoints that facilitate progression through the S/G2/M phase. DNA damage checkpoints activate DNA repair pathways to prevent cell proliferation, which occurs when the genome is damaged. However, research on how cells recommence division after a DNA lesion-induced arrest is insufficient which is merely the result of cancer cells' susceptibility to cell cycle arrest. For example, defects in the G1 arrest checkpoint may cause a cancer cell to proliferate more aggressively, and attempts to fix these complications may cause the cell to grow more slowly and eventually die. Defects in the G2-M arrest checkpoint may enable a damaged cell to enter mitosis and suffer apoptosis, and attempts to boost the effectiveness of chemotherapy may increase its cytotoxicity. Alternatively, attempts to promote G2-M arrest have also been linked to increased apoptosis in the laboratory. Furthermore, variables, such as hyperthermia, contact inhibition, nucleotide shortage, mitotic spindle damage, and resting phase effects, and DNA replication inhibitors add together to halt the cell cycle. In this review, we look at how nucleotide excision repair, MMR, and other variables, such as DNA replication inhibitors, hyperthermia, and contact inhibition, contribute to the outlined processes and functional capacities that cause cell cycle arrest. Ahmed, Muhammad Bilal; Alghamdi, Abdullah A. A.; Ul Islam, Salman; Ahsan, Haseeb; Lee, Young Sup Kyungpook Natl Univ, Sch Life Sci, BK21 FOUR KNU Creat Biores Grp, Daegu 41566, South Korea; Albaha Univ, Fac Sci, Dept Biol, Albaha, Saudi Arabia; Cecos Univ, Dept Pharm, St 1,Sect F 5 Phase 6 Hayatabad, Peshawar, Pakistan; Univ Peshawar, Fac Life & Environm Sci, Dept Pharm, Peshawar 25120, Pakistan; Kyungpook Natl Univ, Coll Nat Sci, Sch Life Sci, Daegu 41566, South Korea ; Ahmed, Muhammad/ABA-8180-2021; Alghamdi, Abdullah/AEO-0020-2022 58689879600; 57410884000; 56985186700; 57531232400; 36013628200 yselee@knu.ac.kr; MINI-REVIEWS IN MEDICINAL CHEMISTRY MINI-REV MED CHEM 1389-5575 1875-5607 23 5 SCIE CHEMISTRY, MEDICINAL 2023 3.3 50.7 2.74 2025-06-25 17 19 NER; MMR; CDKs; DNA replication inhibitors; hyperthermia; contact inhibition NUCLEOTIDE EXCISION-REPAIR; LIGHT-INDUCED APOPTOSIS; MISMATCH REPAIR; DAMAGE RESPONSE; S-PHASE; BODY-TEMPERATURE; CHECKPOINT ACTIVATION; RPA PHOSPHORYLATION; SIGNALING PATHWAYS; HEAT-SHOCK CDKs; Contact inhibition; DNA replication inhibitors; Hyperthermia; MMR; NER Apoptosis; Cell Cycle; Cell Division; Cell Line, Tumor; Contact Inhibition; DNA; DNA Damage; DNA Repair; G2 Phase Cell Cycle Checkpoints; Hyperthermia, Induced; checkpoint kinase 2; cyclin D; cyclin dependent kinase; cyclin E; histone deacetylase inhibitor; iron oxide; nucleotide; protein p21; protein p53; reactive oxygen metabolite; transcriptome; vasculotropin; DNA; apoptosis; cancer cell; cancer inhibition; cell cycle; cell cycle arrest; cell cycle checkpoint; cell cycle G2 phase; cell cycle M phase; cell cycle progression; cell proliferation; cell survival; cell viability; contact inhibition; cytotoxicity; DNA damage; DNA damage checkpoint; DNA repair; DNA replication; Drosophila; excision repair; functional status; G1 phase cell cycle checkpoint; G2 phase cell cycle checkpoint; genetic transcription; genomic instability; histone acetylation; homologous recombination; human; hyperthermia; kinetochore; mismatch repair; mitosis spindle; neural stem cell; nucleotide excision repair; oxidative stress; physiological stress; protein acetylation; protein synthesis; short survey; Short Survey; tissue regeneration; tumor cell; tumor suppressor gene; ubiquitination; wound healing; apoptosis; cell division; DNA repair; thermotherapy; tumor cell line English 2023 2023 10.2174/1389557522666220826141837 바로가기 바로가기 바로가기 바로가기
Article Neuropsychological Activations and Networks While Performing Visual and Kinesthetic Motor Imagery This study aimed to answer the questions 'What are the neural networks and mechanisms involved in visual and kinesthetic motor imagery?', and 'Is part of cognitive processing included during visual and kinesthetic motor imagery?' by investigating the neurophysiological networks and activations during visual and kinesthetic motor imagery using motor imagery tasks (golf putting). The experiment was conducted with 19 healthy adults. Functional magnetic resonance imaging (fMRI) was used to examine neural activations and networks during visual and kinesthetic motor imagery using golf putting tasks. The findings of the analysis on cerebral activation patterns based on the two distinct types of motor imagery indicate that the posterior lobe, occipital lobe, and limbic lobe exhibited activation, and the right hemisphere was activated during the process of visual motor imagery. The activation of the temporal lobe and the parietal lobe were observed during the process of kinesthetic motor imagery. This study revealed that visual motor imagery elicited stronger activation in the right frontal lobe, whereas kinesthetic motor imagery resulted in greater activation in the left frontal lobe. It seems that kinesthetic motor imagery activates the primary somatosensory cortex (BA 2), the secondary somatosensory cortex (BA 5 and 7), and the temporal lobe areas and induces human sensibility. The present investigation evinced that the neural network and the regions of the brain that are activated exhibit variability contingent on the category of motor imagery. Kwon, Sechang; Kim, Jingu; Kim, Teri Korea Sci Acad KAIST, Dept Humanities & Arts, 105-47 Baegyanggwanmun Ro, Busan 47162, South Korea; Korea Adv Inst Sci & Technol KAIST, Global Inst Talented Educ, 291 Daehak Ro, Daejeon 34141, South Korea; Kyungpook Natl Univ, Dept Phys Educ, 80 Daehak Ro, Daegu 41566, South Korea; Kyungpook Natl Univ, Inst Sports Sci, 80 Daehak Ro, Daegu 41566, South Korea Kwon, Sechang/JEF-5352-2023 58117857900; 18835844000; 57824218600 goodsechang@ksa.kaist.ac.kr;terikim@knu.ac.kr; BRAIN SCIENCES BRAIN SCI 2076-3425 13 7 SCIE NEUROSCIENCES 2023 2.7 50.8 1.29 2025-06-25 6 7 visual motor imagery; kinesthetic motor imagery; fMRI; brain network; brain activation; golf putting BRAIN ACTIVATION; MENTAL-IMAGERY; LOCOMOTION; PERCEPTION; PARIETAL; WALKING; CORTEX brain activation; brain network; fMRI; golf putting; kinesthetic motor imagery; visual motor imagery adult; article; clinical article; controlled study; female; frontal lobe; functional magnetic resonance imaging; golf; human; human experiment; imagery; limbic cortex; male; nerve cell network; occipital lobe; parietal lobe; primary somatosensory cortex; right hemisphere; secondary somatosensory cortex; sensibility; temporal lobe English 2023 2023-07 10.3390/brainsci13070983 바로가기 바로가기 바로가기 바로가기
Article The Cerebellar Cortex Receives Orofacial Proprioceptive Signals from the Supratrigeminal Nucleus via the Mossy Fiber Pathway in Rats Proprioceptive sensory information from muscle spindles is essential for the regulation of motor functions. However, little is known about the motor control regions in the cerebellar cortex that receive proprioceptive signals from muscle spindles distributed throughout the body, including the orofacial muscles. Therefore, in this study, we investigated the pattern of projections in the rat cerebellar cortex derived from the supratrigeminal nucleus (Su5), which conveys orofacial proprioceptive information from jaw-closing muscle spindles (JCMSs). Injections of an anterograde tracer into the Su5 revealed that many bilateral axon terminals (rosettes) were distributed in the granular layer of the cerebellar cortex (including the simple lobule B, crus II and flocculus) in a various sized, multiple patchy pattern. We could also detect JCMS proprioceptive signals in these cerebellar cortical regions, revealing for the first time that they receive muscle proprioceptive inputs in rats. Retrograde tracer injections confirmed that the Su5 directly sends outputs to the cerebellar cortical areas. Furthermore, we injected an anterograde tracer into the external cuneate nucleus (ECu), which receives proprioceptive signals from the forelimb and neck muscle spindles, to distinguish between the Su5- and ECu-derived projections in the cerebellar cortex. The labeled terminals from the ECu were distributed predominantly in the vermis of the cerebellar cortex. Almost no overlap was seen in the terminal distributions of the Su5 and ECu projections. Our findings demonstrate that the rat cerebellar cortex receives orofacial proprioceptive input that is processed differently from the proprioceptive signals from the other regions of the body. Tsutsumi, Yumi; Sato, Fumihiko; Furuta, Takahiro; Uchino, Katsuro; Moritani, Masayuki; Bae, Yong Chul; Kato, Takafumi; Tachibana, Yoshihisa; Yoshida, Atsushi Osaka Univ, Dept Oral Anat & Neurobiol, Grad Sch Dent, 1-8 Yamadaoka, Suita, Osaka 5650871, Japan; Takarazuka Univ Med & Hlth Care, Fac Hlth Care Sci, Takarazuka, Hyogo 6660162, Japan; Morinomiya Univ Med Sci, Fac Hlth Sci, Dept Phys Therapy, Osaka 5598611, Japan; Kyungpook Natl Univ, Sch Dent, Dept Anat & Neurobiol, Daegu 700412, South Korea; Osaka Univ, Dept Oral Physiol, Grad Sch Dent, Suita, Osaka 5650871, Japan; Kobe Univ, Div Physiol & Cell Biol, Grad Sch Med, Kobe, Hyogo 6500017, Japan ; Kato, Takafumi/AAF-4017-2020 57196150893; 37112998700; 7201372674; 35742156800; 7003845354; 56377838800; 57210579311; 47461520500; 55757780066 yoshida.atsushi.dent@osaka-u.ac.jp; CEREBELLUM CEREBELLUM 1473-4222 1473-4230 22 4 SCIE NEUROSCIENCES 2023 2.7 50.8 0.95 2025-06-25 5 5 Precerebellar neurons; Muscle spindle; Deep sensation; Trigeminal; Tract tracing RETICULARIS TEGMENTI PONTIS; MUSCLE-SPINDLE AFFERENTS; EXTERNAL CUNEATE NUCLEUS; PONTOCEREBELLAR SYSTEM; TACTILE AREAS; MASTICATORY MOTONEURONS; HORSERADISH-PEROXIDASE; RETROGRADE TRANSPORT; PROJECTION PATTERNS; CEREBRAL-CORTEX Deep sensation; Muscle spindle; Precerebellar neurons; Tract tracing; Trigeminal Animals; Cerebellar Cortex; Mossy Fibers, Hippocampal; Presynaptic Terminals; Rats; Rats, Wistar; biotinylated dextran amine; cholera toxin B subunit; fluorogold; tracer; unclassified drug; animal cell; animal experiment; animal tissue; Article; cerebellum cortex; cerebellum flocculus; cerebellum granular layer; cerebellum vermis; controlled study; crus IIa; crus IIb; cuneate nucleus; forelimb; jaw closing muscle spindle; male; mossy fiber; muscle spindle; neck muscle spindle; nerve ending; nonhuman; orofacial proprioceptive signal; proprioception; rat; simple lobule B; supratrigeminal nucleus; trigeminal nucleus; Wistar rat; animal; hippocampal mossy fiber English 2023 2023-08 10.1007/s12311-022-01434-z 바로가기 바로가기 바로가기 바로가기
Article CCN1 is predominantly elevated in human skin dermis by solar-simulated ultraviolet irradiation and accumulated in dermal extracellular matrix Skin primarily comprises a collagen-rich extracellular matrix (ECM) that provides structural and functional support to the skin. Aging causes progressive loss and fragmentation of dermal collagen fibrils, leading to thin and weakened skin (Dermal aging). We previously reported that CCN1 is elevated in naturally aged human skin, photoaged human skin, and acute UV-irradiated human skin dermal fibroblasts in vivo. Elevated CCN1 alters the expression of numerous secreted proteins that have deleterious effects on the dermal microenvironment, impairing the structural integrity and function of the skin. Here we show that CCN1 is predominantly elevated in the human skin dermis by UV irradiation and accumulated in the dermal extracellular matrix. Laser capture microdissection indicated that CCN1 is predominantly induced in the dermis, not in the epidermis, by acute UV irradiation in human skin in vivo. Interestingly, while UV-induced CCN1 in the dermal fibroblasts and in the medium is transient, secreted CCN1 accumulates in the ECM. We explored the functionality of the matrix-bound CCN1 by culturing dermal fibroblasts on an acellular matrix plate that was enriched with a high concentration of CCN1. We observed that matrix-bound CCN1 activates integrin outside-in signaling resulting in the activation of FAK and its downstream target paxillin and ERK, as well as elevated MMP-1 and inhibition of collagen, in human dermal fibroblasts. These data suggest that accumulation of CCN1 in the dermal ECM is expected to progressively promote the aging of the dermis and thereby negatively impact the function of the dermis. Qin, Zhaoping; He, Tianyuan; Guo, Chunfang; Kim, Jun Young; Quan, Taihao Univ Michigan, Dept Dermatol, Med Sch, 1301 Catherine,Med Sci 1,Room 6447, Ann Arbor, MI 48109 USA; Kyungpook Natl Univ, Sch Med, Dept Dermatol, Daegu, South Korea He, TY/KIB-8606-2024 26428316700; 7202512815; 57202534721; 35310922800; 7005347443 thquan@umich.edu; JOURNAL OF CELL COMMUNICATION AND SIGNALING J CELL COMMUN SIGNAL 1873-9601 1873-961X 17 2 SCIE CELL BIOLOGY 2023 3.6 51.0 0.53 2025-06-25 4 4 CCN1; Aging; Extracellular matrix; UV MULTIFOCAL EPITHELIAL TUMORS; TISSUE GROWTH-FACTOR; FIELD CANCERIZATION; CONNECTIVE-TISSUE; COLLAGEN HOMEOSTASIS; EXPRESSION; INTEGRIN; ACTIVATION; MECHANISMS; REGULATORS Aging; CCN1; Extracellular matrix; UV cell protein; cellular communication network factor 1; collagen; focal adhesion kinase; integrin; interstitial collagenase; mitogen activated protein kinase; paxillin; unclassified drug; vitronectin receptor; adult; aged; aging; Article; controlled study; dermis; epidermis; extracellular matrix; female; human; human cell; human tissue; immunohistology; in vivo study; laser capture microdissection; light damage; male; photoaging; protein binding; protein expression; protein homeostasis; punch biopsy; real time polymerase chain reaction; signal transduction; skin biopsy; skin fibroblast; skin function; ultraviolet irradiation; very elderly; Western blotting English 2023 2023-06 10.1007/s12079-023-00767-6 바로가기 바로가기 바로가기 바로가기
페이지 이동:

논문 데이터 용어 설명

용어 설명
WoS Web of Science. Clarivate Analytics에서 제공하는 학술 데이터베이스입니다. 해당 논문이 WoS에 수록되어 있는지 여부를 표시합니다 (○: 수록됨).
SCOPUS Elsevier에서 제공하는 세계 최대 규모의 초록 및 인용 데이터베이스입니다. 해당 논문이 SCOPUS에 수록되어 있는지 여부를 표시합니다 (○: 수록됨).
Document Type 문헌의 유형을 나타냅니다. Article(원저), Review(리뷰), Proceeding Paper(학회논문), Editorial Material(편집자료), Letter(레터) 등으로 분류됩니다.
Title 논문의 제목입니다.
Abstract 논문의 초록(요약)입니다. 연구의 목적, 방법, 결과, 결론을 간략히 요약한 내용입니다.
Authors 논문의 저자 목록입니다. 공동 저자가 여러 명인 경우 세미콜론(;)으로 구분됩니다.
Affiliation 저자들의 소속 기관 정보입니다. 대학, 연구소, 기업 등 저자가 소속된 기관명이 표시됩니다.
ResearcherID (WoS) Web of Science의 고유 연구자 식별번호입니다. 동명이인을 구분하고 연구자의 업적을 정확하게 추적할 수 있습니다.
AuthorsID (SCOPUS) SCOPUS의 고유 저자 식별번호입니다. 연구자의 모든 출판물을 추적하고 관리하는 데 사용됩니다.
Journal 논문이 게재된 학술지의 정식 명칭입니다.
JCR Abbreviation Journal Citation Reports에서 사용하는 저널의 공식 약어입니다. 저널을 간략하게 표기할 때 사용됩니다.
ISSN International Standard Serial Number. 국제표준연속간행물번호로, 인쇄본 저널에 부여되는 고유 식별번호입니다.
eISSN Electronic ISSN. 전자 버전 저널에 부여되는 고유 식별번호입니다.
Volume 저널의 권(Volume) 번호입니다. 보통 연도별로 하나의 권이 부여됩니다.
Issue 저널의 호(Issue) 번호입니다. 한 권 내에서 여러 호로 나누어 출판되는 경우가 많습니다.
WoS Edition Web of Science의 에디션입니다. SCIE(Science Citation Index Expanded), SSCI(Social Sciences Citation Index), AHCI(Arts & Humanities Citation Index) 등으로 구분됩니다.
WoS Category Web of Science의 주제 분류 카테고리입니다. 저널과 논문이 속한 학문 분야를 나타냅니다.
JCR Year 해당 저널의 JCR(Journal Citation Reports) 지표가 산출된 연도입니다.
IF (Impact Factor) 저널 영향력 지수. 최근 2년간 발표된 논문이 해당 연도에 평균적으로 인용된 횟수를 나타냅니다. 저널의 학술적 영향력을 나타내는 대표적인 지표입니다.
JCR (%) 해당 카테고리에서 저널이 위치하는 상위 백분율입니다. 값이 낮을수록 우수한 저널임을 의미합니다 (예: 5%는 상위 5%를 의미).
FWCI Field-Weighted Citation Impact. 분야별 가중 인용 영향력 지수입니다. 논문이 받은 인용을 동일 분야, 동일 연도, 동일 문헌 유형의 평균과 비교한 값입니다. 1.0이 평균이며, 1.0보다 높으면 평균 이상의 인용을 받았음을 의미합니다.
FWCI UpdateDate FWCI 값이 마지막으로 업데이트된 날짜입니다. FWCI는 인용이 누적됨에 따라 주기적으로 업데이트됩니다.
WOS Citation Web of Science에서 집계된 해당 논문의 총 인용 횟수입니다.
SCOPUS Citation SCOPUS에서 집계된 해당 논문의 총 인용 횟수입니다.
Keywords (WoS) 저자가 논문에서 직접 지정한 키워드입니다. Web of Science에 등록된 저자 키워드 목록입니다.
KeywordsPlus (WoS) Web of Science에서 자동으로 추출한 추가 키워드입니다. 논문의 참고문헌 제목에서 자주 등장하는 단어들로 생성됩니다.
Keywords (SCOPUS) 저자가 논문에서 직접 지정한 키워드입니다. SCOPUS에 등록된 저자 키워드 목록입니다.
KeywordsPlus (SCOPUS) SCOPUS에서 자동으로 추출하거나 추가한 색인 키워드입니다.
Language 논문이 작성된 언어입니다. 대부분 English이며, 그 외 다양한 언어로 작성된 논문이 포함될 수 있습니다.
Publication Year 논문이 출판된 연도입니다.
Publication Date 논문의 정확한 출판 날짜입니다 (년-월-일 형식).
DOI Digital Object Identifier. 디지털 객체 식별자로, 논문을 고유하게 식별하는 영구적인 식별번호입니다. 이를 통해 논문의 온라인 위치를 찾을 수 있습니다.